Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
Key Highlights
- ➤Q3 operating expenses $5.9 million, down 36% year over year
- ➤Q3 net loss $5.638 million, versus $8.692 million loss in 2025
- ➤Cash and equivalents $20.574 million at September 30, down from $41.299 million
- ➤CVR holders entitled to 25% of first PRV proceeds, capped at $50 million
- ➤FDA IND clearance for (Z)-endoxifen in DMD and MAS anticipated by early 2027
Expert Statements
Steven C. Quay, Chairman, President and Chief Executive Officer of Atossa Therapeutics
“In recent weeks, we took meaningful steps to enable shareholders to participate in potential future value from our rare disease programs.”
Steven C. Quay, Chairman, President and Chief Executive Officer of Atossa Therapeutics
“Our recently announced contingent value rights agreement entitles holders to share in 25% of the net proceeds, up to $50 million, from the sale of the first priority review voucher awarded to Atossa from its rare disease development programs.”
Steven C. Quay, Chairman, President and Chief Executive Officer of Atossa Therapeutics
“At the same time, we continued to advance (Z)-endoxifen toward several near-term milestones, including anticipated FDA clearance of our IND applications in Duchenne Muscular Dystrophy and McCune-Albright Syndrome in early 2027.”
Steven C. Quay, Chairman, President and Chief Executive Officer of Atossa Therapeutics
“In December 2026, presentations at the San Antonio Breast Cancer Symposium will include Karisma follow-up results and selected data from the ongoing I-SPY2 study evaluating (Z)-endoxifen in combination with other therapies.”
Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update PR Newswire
SEATTLE, Nov. 10, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced its financial results for the third quarter ended September 30, 2026 and provided an update on recent corporate developments.
Get started
Create a free account to read the full story.